Moving on from Usama Malik’s insider trading imbroglio, Fore resets at the top; Takeda spinout turns to Neurana CEO to lead the way

Matthew Ros

→ The ouster of former Immunomedics exec Usama Malik created a CEO opening at Fore Biotherapeutics, which is taking aim at BRAF mutations following a rebrand last year. Matthew Ros has now stepped up to the tee box as...

Click to view original post